Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of ZED1227 capsules with placebo in the treatment of non-alcoholic fatty liver disease (NAFLD) with significant fibrosis
Latest Information Update: 22 Sep 2024
At a glance
- Drugs ZED 1227 (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Acronyms NormaliZED
- Sponsors Dr Falk Pharma
Most Recent Events
- 13 May 2024 Status changed from recruiting to completed.
- 07 Sep 2023 This trial has been completed in Germany and Poland (End Date: 05 Jul 023), according to European Clinical Trials Database record.
- 26 Jul 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.